NCT00758849 - Fipamezole in Neurogenic Orthostatic Hypotension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Symptomatic Neurogenic Orthostatic Hypotension (NOH)Parkinson's DiseaseMultiple System Atrophy

Interventions

DRUG

Placebo

One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout

DRUG

Fipamezole

One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout

Trial Locations (4)

29609

Hôpital de la Cavale Blanche, CHU Brest, Brest

31059

Hôpital Purpan CIC du CHU de Toulouse, Toulouse

33604

Hôpital du Haut Lévêque, CHU de Bordeaux, Bordeaux

1649-028

Centro de Estudos Egas Moniz, Faculdade de Medicina de Lisboa, Lisbon